서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 10 of 10

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2014-08	Radiation sensitizing effect of combined use of olaparib and PI-103 and its mechanism in triple negative breast cancer 장나영	view file
2015-03	Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer Jang, Na Young; Kim, Dan Hyo; Cho, Bong Jun; Choi, Eun Jung; Lee, Jong-Soo; Wu, Hong-Gyun; Chie, Eui Kyu; Kim, In Ah BMC Cancer, 15(1):89	view file DOI
2019-04	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Robson, M. E.; Tung, N.; Conte, P.; Im, S. -A.; Senkus, E.; Xu, B.; Masuda, N.; Delaloge, S.; Li, W.; Armstrong, A.; Wu, W.; Goessl, C.; Runswick, S.; Domchek, S. M. Annals of Oncology, Vol.30 No.4, pp.558-566	DOI
2019-11	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers Sa, Jason K.; Hwang, Jae Ryoung; Cho, Young-Jae; Ryu, Ji-Yoon; Choi, Jung-Joo; Jeong, Soo Young; Kim, Jihye; Kim, Myeong Seon; Paik, E. Sun; Lee, Yoo-Young; Choi, Chel Hun; Kim, Tae-Joong; Kim, Byoung-Gie; Bae, Duk-Soo; Lee, Yeri; Her, Nam-Gu; Shin, Yong Jae; Cho, Hee Jin; Kim, Ja Yeon; Seo, Yun Jee; Koo, Harim; Oh, Jeong-Woo; Lee, Taebum; Kim, Hyun-Soo; Song, Sang Yong; Seol, Joon; Park, Woong-Yang; Han, Hee Dong; Ahn, Hyung Jun; Sood, Anil K.; Rabadan, Raul; Lee, Jin-Ku; Nam, Do-Hyun; Lee, Jeong-Won Genome Biology, Vol.20 No.1, p. 253	DOI
2021	Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells : Combined therapy with chk1 inhibitor and Rucaparib in ovarian cancer 조혜연	view file link
2021	DNA Damage Repair Inhibitor for Breast Cancer Treatment Min, Ahrum; Lee, Kyung-Hun; Im, Seock-Ah Advances in Experimental Medicine and Biology, Vol.1187, pp.159-179	DOI
2021-10	Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial Lee, Kyung-Hun; Sohn, Joohyuk; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Im, Seock-Ah; Kim, Sung-Bae Cancer Research and Treatment, Vol.53 No.4, pp.1084-1095	DOI
2022-06	Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors Mekonnen, Negesse; Yang, Hobin; Shin, Young Kee Frontiers in Oncology, Vol.12, p. 880643	DOI
2023-05	OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco European Journal of Cancer, Vol.184, pp.39-47	DOI
2023-08	Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial Senkus, Elzbieta; Delaloge, Suzette; Domchek, Susan M.; Conte, Pierfranco; Im, Seock-Ah; Xu, Binghe; Armstrong, Anne; Masuda, Norikazu; Fielding, Anitra; Robson, Mark; Tung, Nadine International Journal of Cancer, Vol.153 No.4, pp.1-12	DOI

1